Candel Therapeutics, Inc. (CADL) — Financial statements
Income statement, balance sheet, and cash flow for Candel Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00↓100.0% | 0.13↑0.0% | 0.13 | |
| Cost of Revenue | 0.85↓14.6% | 0.99↓95.9% | 24 | 0.00↓100.0% | 15 | |
| Gross Profit | -0.85↑14.6% | -0.99↑95.9% | -24↓19284.0% | 0.13↑100.9% | -14 | |
| Operating Expenses | ||||||
| R&D Expenses | 30↑57.9% | 19↓21.2% | 25↑17.9% | 21↑37.0% | 15 | |
| General & Administrative Expenses | 18↑26.4% | 14↑2.4% | 14↓2.4% | 14↑34.9% | 10 | |
| Selling & Marketing Expenses | 0.00 | 0.00↓100.0% | 0.69 | 0.00↓100.0% | 0.83 | |
| SG&A Expenses | 18↑26.4% | 14↓2.5% | 14↑2.5% | 14↑24.9% | 11 | |
| Other Expenses | -0.85↑14.6% | -0.99↑96.0% | -25 | 0.00↑100.0% | -15 | |
| Operating Expenses | 47↑46.4% | 32↑124.7% | 14↓58.6% | 35↑209.6% | 11 | |
| Total Costs & Expenses | 48↑44.6% | 33↓13.1% | 38↑10.2% | 35↑34.8% | 26 | |
| Operating Results | ||||||
| Operating Income | -48↓44.6% | -33↑13.1% | -38↓10.6% | -35↓35.0% | -26 | |
| Depreciation & Amortization | 0.85↓14.6% | 0.99↑3.1% | 0.96↑23.4% | 0.78↑235.3% | 0.23 | |
| EBITDA | -47↑9.0% | -52↓39.2% | -37↓129.5% | -16↑36.0% | -25 | |
| EBIT | -48↑9.1% | -53↓38.3% | -38↓124.7% | -17↑33.6% | -26 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↑278.9% | -1↓95.3% | -0.51↓4.9% | -0.49↓824.5% | -0.05 | |
| Interest Income | 4↑260.5% | 1 | 0.00↓100.0% | 1 | 0.00 | |
| Interest Expense | 2↑1.4% | 2↑306.6% | 0.51↓69.9% | 2↑3122.6% | 0.05 | |
| Non-Operating Income | 0.00↓100.0% | 20 | 0.00↑100.0% | -18 | 0.00 | |
| Other Income / Expenses | 10↑146.2% | -22↓4924.3% | 0.45↓97.2% | 16↑253.2% | -10 | |
| Income Before Tax | -38↑30.8% | -55↓45.4% | -38↓101.9% | -19↑48.0% | -36 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -38↑30.8% | -55↓45.4% | -38↓101.9% | -19↑48.0% | -36 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -38↑30.8% | -55↓45.4% | -38↓101.9% | -19↑48.0% | -36 | |
| Bottom-Line Net Income | -38↑30.8% | -55↓45.4% | -38↓101.9% | -19↑48.0% | -36 | |
| EPS (Basic) | -0.72↑58.6% | -1.74↓32.8% | -1.31↓1217.9% | -0.10↑92.1% | -1.26 | |
| EPS (Diluted) | -0.72↑58.6% | -1.74↓32.8% | -1.31↓1217.9% | -0.10↑92.1% | -1.26 | |
| Weighted Average Shares | 53↑67.2% | 32↑9.5% | 29↑0.4% | 29↑0.5% | 29 | |
| Weighted Average Diluted Shares | 53↑67.2% | 32↑9.5% | 29↑0.4% | 29↑0.5% | 29 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.